Atrial fibrillation (AF) is the most commonly encountered sustained cardiac arrhythmia (abnormal heart rhythm), and involves the two upper chambers (atria) of the heart. Its name comes from the abnormal fibrillating (i.e. quivering) of the heart muscles of the atria instead of the normal coordinated contraction.
AF prevalence increases with age with an estimated 9% prevalence in patients ages >65. It is estimated that up to 6 million people in the United States have AF; This number is expected to double by 20501-3.
AF is associated with a significant morbidity and a substantial reduction of quality of life in some patients. The consequences of atrial fibrillation range from none to debilitating, including:
AF is thought to be responsible for 15% of the strokes occurring in elderly patients1. Furthermore, AF is associated with a 50% to 100% increased risk of death4. Besides age, known risk factors for AF include hypertension, left ventricular hypertrophy (increased heart muscle thickness), diabetes, and cigarette smoking5.
AF contributes significant cost to the US healthcare system:
Approximately 40% of patients with AF have paroxysmal atrial fibrillation, a type of AF where episodes terminate in less than 7 days. About 1 in 4 people with paroxysmal atrial fibrillation eventually develop the permanent form of the condition within 5 years7. Common symptoms of PAF can include:
Today’s treatment options for episodes of PAF have several shortcomings, including:
Due to these limitations, PAF patients often require hospitalization from the ER.
There is a need for a treatment option that safely and promptly restores sinus rhythm and reduces burden to the healthcare system.
1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285(18):2370-5.
2. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130(23):2071-104.
3. Chugh SS, Roth GA, Gillum RF, Mensah GA, Glob Heart. 2014 Mar;9(1):113-9
4. American Heart Association website “What are the Symptoms of Atrial Fibrillation (AFib or AF)?” www.heart .org (accessed July 2018).
5. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82(8A):2N-9N.
6. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37(38):2893-2962.
7. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, Boone J, Sheldon R, Dorian P, Newman D; Am Heart J. 2005 Mar;149(3):489-96
8. Cosio FG1, Aliot E, Botto GL, Heidbüchel H, Geller CJ, Kirchhof P, De Haro JC, Frank R, Villacastin JP, Vijgen J, Crijns H, Europace. 2008 Jan;10(1):21-7. Epub 2007 Dec 17
9. Kim et al, Circulation 2011
10. Rozen, Ruskin et al. J Am Heart Assoc. 2018
11. Go et al, JAMA 2001
12. Nattel S, Guasch E, Savelieva I, et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J. 2014;35:1448-1456.